Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1020"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1394"
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:Evidence_assump_list_id	"182"
?:Evidence_enzyme_system	""
?:claim_assumed_valid_for_evidence_application_evidence_1394	?:desipramine_primary_total_clearance_enzyme_cyp2d6
dc:creator	"boycer"
dc:date	"05/15/2009 10:11:58"
?:content	"7.19 Drugs Metabolized by Cytochrome P4502D6 In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6."
rdfs:seeAlso	?:13bb8267-1cab-43e5-acae-55a4d957630a

The resource appears as object in one triple:

{ escitalopram_inhibits_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1394 }

Context graph